Companies → Zenas BioPharma, Inc.

Save to list

Remove

Zenas BioPharma, Inc.

United States, Waltham

Report a bug?

Claim ownership and edit

Description

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Industries

Wood Product Manufacturing

SIC

Lumber and Wood Products, Except Furniture

Address:

852 Winter Street

Website:

zenasbio.com

Revenue

Recent news:

ENAVATE Sciences Expands Zenas BioPharma Stake to $142.3M

ENAVATE Sciences significantly increased its investment in Zenas BioPharma, making it the firm's largest portfolio holding at 28.08% of its reportable assets, as detailed in a recent SEC filing.

Source: IndexBox Mar 21, 2026

The Resurgence of Meme Stocks: A New Wave of Investment Opportunities

Explore the resurgence of meme stocks such as Airsculpt Technologies, Children's Place, and Zenas Biopharma, driven by high short interest and market dynamics.

Source: IndexBox Aug 2, 2025

XNAS - Delayed Quote - USD

ZBIO

22.30 -1.07 (-4.58%)

At close March 23 02:32 UTC

Candle

Line

Financial Statistics

Valuation Measures

Current

Quarterly

As of 06/22/2025

Market Cap: 385.71 M

Enterprise Value: 74.56 M

Trailing P/E: N/A

Forward P/E: -2.41

PEG Ratio (5yr expected): N/A

Price/Sales (ttm): 25.71

Price/Book (mrq): 1.36

Enterprise Value/Revenue: 4.97

Enterprise Value/EBITDA: -0.42

Financial Highlights

Profitability and Income Statement

Profit Margin: N/A%

Return on Assets (ttm): -56.70%

Return on Equity (ttm): -115.47%

Revenue (ttm): 15.00 M

Net Income Avi to Common (ttm): -162.76 M

Diluted EPS (ttm): -3.89

Balance Sheet and Cash Flow

Total Cash (mrq): 312.38 M

Total Debt/Equity (mrq): 0.43%

Levered Free Cash Flow (ttm): -77.74 M

Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.